2-甲氧基-6-甲基苯甲酰胺 | 139583-90-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2-甲氧基-6-甲基苯甲酰胺
• 中文别名: 2-甲基-6-甲氧基苯甲酰胺
• 英文名称: 2-methoxy-6-methylbenzamide
• 英文别名: 2-methoxy-6-methyl-benzoic acid amide；2-Methoxy-6-methyl-benzoesaeure-amid；6-Methoxy-2-methyl-benzamid
• CAS: 139583-90-7
• 化学式: C₉H₁₁NO₂
• 分子量: 165.192
• InChiKey: IRQLMNZDQZOWMP-UHFFFAOYSA-N

物化性质

• 沸点：
  269.4±33.0 °C(Predicted)
• 密度：
  1.113±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  52.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-甲氧基-6-甲基苯甲酰胺 在 吡啶 、 三氟乙酸酐 作用下， 以 二氯甲烷 为溶剂， 以91%的产率得到2-甲氧基-6-甲基苯甲腈
  参考文献：
  名称：

  Heteroatom-directed metalation. Lithiation of N-propenylbenzamides and N-propenyl-o-toluamides. Novel routes to ortho-substituted primary benzamide derivatives and N-unsubstituted isoquinolin-1(2H)-ones

  摘要：

  Reaction of N-propenylbenzamides 4 and 9, obtained by LDA-induced isomerization of the corresponding N-allylbenzamides 1, 8, and 14, with 2 equiv of sec-butyllithium or tert-butyllithium at low temperature regiospecifically generates the highly reactive N,ortho-dilithiated species (e.g., 5 and 17). These dilithio species react avidly with a wide spectrum of electrophilic reagents, including alkyl halides, giving adducts which on hydrolysis with warm 50% aqueous acetic acid are converted into ortho-substituted primary benzamides in excellent yields. Ortho-lithiation of N-propenylbenzamides is thus formally equivalent to ortho-lithiation of primary benzamides themselves. The utility of this important, previously unknown, synthetic operation is enhanced by the well-known facility with which the primary amide moiety can be transformed into other useful functional groups, as exemplified by the synthesis of 2-methoxy-6-methylbenzoic acid (12) and 2-methoxy-6-methylbenzonitrile (13) from N-propenyl-2-methoxybenzamide (9), N-Propenyl-o-toluamide (7) undergoes regiospecific dilithiation on nitrogen and on the methyl group under conditions analogous to those used for the N-propenylbenzamides. These dilithio species react with DMF or "Weinreb type" amides to give condensation products which cyclize to N-propenylisoquinolin-1(2H)-ones under midly acidic conditions. Removal of the N-propenyl moiety under more strongly acidic conditions provides N-unsubstituted isoquinolin-1(2H)-ones with high overall efficiency. This process is exemplified by the synthesis of isoquinolin-1(2H)-one (23) and its 3-n-butyl congener 26 from N-propenyl-2-methylbenzamide (7).

  DOI：

  10.1021/jo00035a030
• 作为产物：
  描述：

  2-甲氧基-6-甲基苯甲腈 在 sodium hydroxide 作用下， 生成 2-甲氧基-6-甲基苯甲酰胺
  参考文献：
  名称：

  Gibson, Journal of the Chemical Society, 1923, vol. 123, p. 1272

  摘要：

  DOI：

文献信息

• Pyrrole Derivatives As Pharmaceutical Agents
  申请人：Canne Bannen Lynne

  公开号：US20080234270A1

  公开（公告）日：2008-09-25

  Compounds, compositions and methods for modulating the activity of receptors are provided. In particular compounds and compositions are provided for modulating the activity of receptors and for the treatment, prevention, or amelioration of one or more symptoms of disease or disorder directly or indirectly related to the activity of the receptors.

  提供了用于调节受体活性的化合物、组合物和方法。特别提供了用于调节受体活性的化合物和组合物，以及用于治疗、预防或改善与受体活性直接或间接相关的一种或多种疾病或紊乱的症状的方法。
• [EN] N-ARYL-2-(2-ARYLAMINOPYRIMIDIN-4-YL)PYRROL-4-CARBOXAMIDE DERIVATIVES AS MPS1 KINASE INHIBITORS<br/>[FR] DÉRIVÉS DE N-ARYL-2-(2-ARYLAMINOPYRIMIDIN-4-YL)PYRROL-4-CARBOXAMIDE À TITRE D'INHIBITEURS DE KINASE MPS1
  申请人：NERVIANO MEDICAL SCIENCES SRL

  公开号：WO2010108921A1

  公开（公告）日：2010-09-30

  The present invention relates to substituted pyrrolyl-pyrimidines which modulate the activity of protein kinases and are therefore useful in treating diseases caused by dysregulated protein kinase activity, in particular MPS1. The present invention also provides methods for preparing these compounds, pharmaceutical compositions comprising these compounds, and methods of treating diseases utilizing such these compounds or the pharmaceutical compositions containing them.

  本发明涉及替代吡咯基嘧啶，其调节蛋白激酶活性，因此在治疗由失调的蛋白激酶活性引起的疾病方面具有用处，特别是MPS1。本发明还提供了制备这些化合物的方法，包括这些化合物的药物组合物，以及利用这些化合物或含有它们的药物组合物治疗疾病的方法。
• [EN] PYRIDONEAMIDE DERIVATIVES AS FOCAL ADHESION KINASE (FAK) INHIBITORS AND THEIR USE FOR THE TREATMENT OF CANCER<br/>[FR] DÉRIVÉS DE PYRIDONÉAMIDE EN TANT QU'INHIBITEURS DE LA KINASE D'ADHÉSION FOCALE (FAK) ET LEUR UTILISATION POUR LE TRAITEMENT DU CANCER
  申请人：HOFFMANN LA ROCHE

  公开号：WO2009024332A1

  公开（公告）日：2009-02-26

  Objects of the present invention are the compounds of formula (I) their pharmaceutically acceptable salts, enantiomeric forms, diastereoisomers and racemates, the preparation of the above-mentioned compounds, medicaments containing them and their manufacture, as well as the use of the above-mentioned compounds in the control or prevention of illnesses such as cancer.

  本发明的对象是公式(I)的化合物及其药用盐、对映体形式、二对映异构体和混合物，上述化合物的制备，含有它们的药物以及它们的制造，以及上述化合物在控制或预防癌症等疾病中的用途。
• Urea Derivative
  申请人：Kurata Hitoshi

  公开号：US20070249620A1

  公开（公告）日：2007-10-25

  The present invention relates to a urea derivative or a pharmacologically acceptable salt thereof having an excellent DGAT inhibitory effect. A urea derivative having the formula: [wherein R 1 is a C 6 -C 10 aryl group which may be independently mono- to pentasubstituted by a group selected from Substituent Group a or others; R is a C 6 -C 10 aryl group which may be independently mono- to pentasubstituted by a group selected from Substituent Group a or others; E is a group having the formula (II) or the formula (III) (wherein R 3 is a hydrogen atom or others; R 4 and R 5 , which are the same or different, are a hydrogen atom or others; X and U, which are the same or different, are a group represented by the formula CH or others; m and n, which are the same or different, are I or another number) or others; and A is a group represented by the formula —NH—C(═O)— or others], or a pharmacologically acceptable salt thereof.

  本发明涉及一种具有出色DGAT抑制作用的脲衍生物或其药理学上可接受的盐。其中，该脲衍生物具有以下公式：[式中，R1是C6-C10芳基，可以独立地被来自置换基团a或其他的基团单独到五重取代；R是C6-C10芳基，可以独立地被来自置换基团a或其他的基团单独到五重取代；E是具有公式（II）或公式（III）的基团（其中，R3是氢原子或其他；R4和R5相同或不同，是氢原子或其他；X和U相同或不同，是由公式CH或其他表示的基团；m和n相同或不同，是I或其他数字）或其他；A是由公式—NH—C(═O)—或其他表示的基团]，或其药理学上可接受的盐。
• UREA DERIVATIVE
  申请人：Sankyo Company, Limited

  公开号：EP1764360A1

  公开（公告）日：2007-03-21

  The present invention relates to a urea derivative or a pharmacologically acceptable salt thereof having an excellent DGAT inhibitory effect. A urea derivative having the formula: [wherein R1 is a C6-C10 aryl group which may be independently mono- to pentasubstituted by a group selected from Substituent Group a or others; R2 is a C6-C10 aryl group which may be independently mono- to pentasubstituted by a group selected from Substituent Group a or others; E is a group having the formula (II) or the formula (III) (wherein R3 is a hydrogen atom or others; R4 and R5, which are the same or different, are a hydrogen atom or others; X and U, which are the same or different, are a group represented by the formula CH or others; m and n, which are the same or different, are 1 or another number) or others; and A is a group represented by the formula -NH-C(=O)- or others], or a pharmacologically acceptable salt thereof.

  本发明涉及一种脲衍生物或其药理上可接受的盐，具有极佳的 DGAT 抑制作用。一种脲衍生物具有以下式子： [其中 R1 是 C6-C10 芳基，可独立地被选自取代基 a 或其它的基团一至五取代；R2 是 C6-C10 芳基，可独立地被选自取代基 a 或其它的基团一至五取代；E 是具有式(II)或式(III)的基团（其中 R3 是氢原子或其它；R4和R5相同或不同，为氢原子或其它；X和U相同或不同，为式CH代表的基团或其它；m和n相同或不同，为1或其它数字）或其它；以及A为式-NH-C(=O)-代表的基团或其它]，或其药理学上可接受的盐。